



CMWG-7, Annecy, 5-7 March 2013

Venue: Les Pensières, Centre de Conférence de la Fondation Mérieux
55, route d'Annecy, Vieille route des Pensières, 74290 Veyrier du Lac, France

AGENDA

Day 1		5 March 2013	
8.30 – 9.00	Registration		
Session 1	Opening Session	(Chair: Patrick Kachur)	
9.00 – 9.10	Welcoming remarks and opening of CMWG-7, <i>Patrick Kachur (CMWG Co-chair)</i>		
9.10 – 9.25	Introduction, <i>Patrick Kachur (CMWG Co-chair)</i> <ul style="list-style-type: none">▪ Approval CMWG-6 minutes, CMWG-7 objectives and agenda▪ Introduction of participants		
9.25 – 9.30	CMWG Co-chair election, <i>Jan Van Erps (RBM secretariat)</i>		
Session 2	Diagnosis Updates	Short presentations (10min)	(Chair: Patrick Kachur)
9.30 – 9.45	Update from the Diagnosis Workstream, <i>Larry Barat (PMI)</i>		
9.45 – 10.00	Assessment of country training and supervision materials and adherence to updated WHO guidance, <i>Larry Barat (PMI)</i>		
10.00 – 10.15	Report on WHO consultation on the management of fever in peripheral settings, <i>Andrea Bosman (WHO/GMP), Valérie D'Acromont (Swiss TPH)</i>		
10.15 – 10.30	Short discussion		
10.30 – 11.00	Coffee break		
11.00 – 11.15	Experiences and lessons learned with scaling up diagnosis and treatment in the private sector, <i>David Schellenberg (ACT Consortium)</i>		
11.15 – 11.30	Experiences and lessons learned with scaling up diagnosis and treatment in the private sector, <i>Tanya Shewchuk (PSI)</i>		
11.30 – 12.00	Country experiences: <ul style="list-style-type: none">• Zimbabwe, <i>Standford Mashaire (NMCP)</i>• Sierra Leone, <i>Samuel Juana Smith (NMCP)</i>		
12.00 – 12.30	Discussion		
12.30 – 13.30	Lunch		
Session 3	Pharmacovigilance Updates	Short presentations (10min)	(Chair: Patrick Kachur)
13.30 – 13.45	Update from the Pharmacovigilance Workstream, <i>Alex Doodoo (University of Ghana), Serge Xueref (WHO/EMP)</i>		



- 13.45 – 14.00 **WHO Pharmacovigilance guidance**, *Serge Xueref (WHO/EMP)*
- 14.00 – 14.15 **A Centralized Safety Repository**, *Cheryl Pace (ACT Consortium)*
- 14.15 – 14.30 **Phase IV studies and post-marketing safety – MMV’s perspective**, *Stephan Duparc (MMV)*
- 14.30 – 15.30 **Discussion**

15.30 – 16.00 **Coffee break**

Session 4 Break-out session : four workstreams break apart

16.00 -18.00 **Access, Diagnosis, Pharmacovigilance and Resistance Workstreams discuss priorities for action, and dissemination of products**

18.00 – 20.00 **Cocktail**

Day 2

6 March 2013

Session 5 Drug resistance updates Short presentations (10min) (Chair: Patrick Kachur)

- 8.45 – 9.00 **Update of the Drug Resistance Workstream**, *Sylvia Meek (Malaria Consortium)*
- 9.00 – 9.15 **WHO resistance situation report**, *Andrea Bosman (WHO/GMP)*
- 9.15 – 9.30 **Summary of last year’s joint strategic assessment of artemisinin resistance containment and the Australia Malaria 2012 Conference**, *Sylvia Meek (Malaria Consortium)*
- 9.30 – 9.45 **Meeting the threat of anti-malarial drug resistance – WWARN’s contribution**, *Philippe Guérin (WWARN)*
- 9.45 – 10.30 **Discussion**

10.30 – 11.00 **Coffee break**

Session 6 Access updates Short presentations (10min) (Chair: Patrick Kachur)

- 11.00 – 11.15 **Update from the Access Workstream**, *Shannon Downey (Core Group)*
- 11.15 – 11.30 **Supporting uptake of newly available WHO recommended treatments**, *Penny Grewal (MMV)*
- 11.30 - 11.45 **Artesunate injections - practical aspects**, *Martin De Smet (MSF)*
- 11.45 – 12.00 **Seasonal Malaria Chemoprevention (SMC) and its implication for case management**, *Peter Olumese (WHO/GMP)*
- 12.00 – 12.15 **Semi-synthetic Artemisinin and global ACT availability over the next years**, *Malcolm Cutler (A2S2)*
- 12.15 – 13.00 **Discussion**

13.00 – 14.00 **Lunch**



14.00 – 14.30	Country experiences: <ul style="list-style-type: none"> • Zanzibar, <i>Mwinyi I. Msellem (NMCP)</i> • Cameroon, <i>Dorothy Achu (NMCP)</i> • Niger, <i>Hadiza Jackou Djermakoye (NMCP)</i>
14.30 – 14.45	Support to countries for transition and integration of the AMFm into the New Funding Model of the Global Fund , <i>Peter Olumese (RBM AMFm Workstream)</i>
14.45 – 15.00	Scaling up malaria diagnosis and treatment in the private sector , <i>Alan Court (AMFm Taskforce)</i>
15.00 – 15.30	Discussion
15.30 – 16.00	Coffee break
Session 7	Break-out session : three workstreams break apart
16.00 -18.00	Access, Diagnosis and Resistance Workstreams discuss priorities for action, and dissemination of products
18.00	End of Day 2

Day 3

7 March 2013

Session 8	Reports from break-out sessions and discussion	(Chair: Patrick Kachur)
9.00 – 10.30	<ul style="list-style-type: none"> • Diagnosis, <i>Larry Barat (PMI)</i> • Pharmacovigilance, <i>Serge Xueref (WHO/EMP)</i> • Drug resistance, <i>Sylvia Meek (Malaria Consortium)</i> • Expanding Access to treatment, <i>Shannon Downey (Core Group)</i> <p>Integrated Community Case Management (iCCM): Rapid Access Expansion project (RACE 2015), <i>Franco Pagnoni (WHO/GMP)</i></p>	
10.30 – 11.00	Coffee break	
Session 9	Summary and closure of the CMWG-7	(Chair: Patrick Kachur)
11.00 – 12.30	<ul style="list-style-type: none"> ▪ Key priorities ▪ Outstanding issues/parking lot and CMWG next steps ▪ Next CMWG meeting date 	
12.30	Close of CMWG-7	